 Julie Fitzgerald
Concepts (443)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 44 | 2023 | 270 | 8.900 |
Why?
| | Shock, Septic | 26 | 2022 | 79 | 5.040 |
Why?
| | Acute Kidney Injury | 17 | 2021 | 269 | 3.770 |
Why?
| | Child | 104 | 2023 | 6582 | 2.990 |
Why?
| | Intensive Care Units, Pediatric | 29 | 2021 | 91 | 2.970 |
Why?
| | Systemic Inflammatory Response Syndrome | 14 | 2022 | 46 | 2.550 |
Why?
| | Child, Preschool | 61 | 2022 | 3556 | 2.170 |
Why?
| | Multiple Organ Failure | 9 | 2022 | 42 | 1.960 |
Why?
| | Infant | 49 | 2022 | 2947 | 1.850 |
Why?
| | Hospital Mortality | 16 | 2022 | 323 | 1.620 |
Why?
| | Hypotension | 2 | 2020 | 66 | 1.480 |
Why?
| | Critical Care | 13 | 2022 | 351 | 1.440 |
Why?
| | Adolescent | 57 | 2023 | 8712 | 1.400 |
Why?
| | Hematopoietic Stem Cell Transplantation | 11 | 2022 | 824 | 1.200 |
Why?
| | Vancomycin | 4 | 2022 | 75 | 1.150 |
Why?
| | Anti-Bacterial Agents | 10 | 2022 | 708 | 1.130 |
Why?
| | Retrospective Studies | 42 | 2023 | 7526 | 1.120 |
Why?
| | Respiratory Insufficiency | 7 | 2022 | 141 | 1.030 |
Why?
| | Humans | 117 | 2023 | 80727 | 1.020 |
Why?
| | Cytokines | 6 | 2022 | 752 | 1.010 |
Why?
| | Heart Arrest | 4 | 2019 | 257 | 0.980 |
Why?
| | Kidney Diseases | 3 | 2022 | 409 | 0.970 |
Why?
| | Bacterial Infections | 3 | 2020 | 183 | 0.930 |
Why?
| | Severity of Illness Index | 19 | 2021 | 1695 | 0.920 |
Why?
| | Critical Illness | 12 | 2022 | 264 | 0.920 |
Why?
| | Hospitals, Pediatric | 11 | 2022 | 97 | 0.890 |
Why?
| | Shock | 3 | 2021 | 42 | 0.890 |
Why?
| | Intensive Care Units | 6 | 2022 | 349 | 0.840 |
Why?
| | Male | 70 | 2023 | 39628 | 0.840 |
Why?
| | Female | 68 | 2023 | 42509 | 0.810 |
Why?
| | Immunocompromised Host | 1 | 2020 | 134 | 0.760 |
Why?
| | Prospective Studies | 24 | 2022 | 3934 | 0.750 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 332 | 0.750 |
Why?
| | Databases as Topic | 1 | 2019 | 90 | 0.730 |
Why?
| | Intubation, Intratracheal | 5 | 2022 | 137 | 0.710 |
Why?
| | Vaccination | 1 | 2020 | 236 | 0.710 |
Why?
| | Adaptation, Psychological | 1 | 2018 | 152 | 0.660 |
Why?
| | Infant, Newborn | 16 | 2022 | 2276 | 0.650 |
Why?
| | Heart Diseases | 1 | 2019 | 289 | 0.620 |
Why?
| | Risk Factors | 16 | 2022 | 5143 | 0.610 |
Why?
| | Leukemia | 1 | 2018 | 311 | 0.600 |
Why?
| | High-Frequency Ventilation | 2 | 2013 | 9 | 0.590 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 221 | 0.580 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2017 | 370 | 0.570 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2017 | 132 | 0.560 |
Why?
| | Cross-Sectional Studies | 9 | 2022 | 1394 | 0.520 |
Why?
| | Immunotherapy | 4 | 2021 | 564 | 0.480 |
Why?
| | Prognosis | 14 | 2022 | 3539 | 0.460 |
Why?
| | Prevalence | 11 | 2022 | 1179 | 0.440 |
Why?
| | Respiration, Artificial | 7 | 2020 | 326 | 0.440 |
Why?
| | Quality of Life | 2 | 2020 | 1388 | 0.440 |
Why?
| | Emergencies | 1 | 2011 | 106 | 0.430 |
Why?
| | Nervous System Diseases | 2 | 2023 | 143 | 0.430 |
Why?
| | Brain Diseases | 2 | 2022 | 174 | 0.420 |
Why?
| | Coronavirus Infections | 3 | 2020 | 283 | 0.420 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 302 | 0.420 |
Why?
| | Blood Transfusion | 2 | 2022 | 150 | 0.420 |
Why?
| | Trachea | 1 | 2011 | 292 | 0.410 |
Why?
| | Glomerular Filtration Rate | 3 | 2022 | 377 | 0.400 |
Why?
| | Length of Stay | 8 | 2021 | 656 | 0.400 |
Why?
| | Anti-Infective Agents | 2 | 2021 | 82 | 0.390 |
Why?
| | United States | 19 | 2023 | 6146 | 0.390 |
Why?
| | Drug Monitoring | 2 | 2021 | 114 | 0.380 |
Why?
| | Hypothermia, Induced | 2 | 2021 | 71 | 0.380 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2021 | 50 | 0.370 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2018 | 13 | 0.360 |
Why?
| | Immunotherapy, Adoptive | 2 | 2021 | 143 | 0.360 |
Why?
| | Resuscitation | 3 | 2017 | 81 | 0.350 |
Why?
| | Emergency Service, Hospital | 3 | 2017 | 417 | 0.350 |
Why?
| | HSP70 Heat-Shock Proteins | 4 | 2017 | 110 | 0.350 |
Why?
| | Young Adult | 15 | 2022 | 5735 | 0.350 |
Why?
| | Algorithms | 5 | 2020 | 1778 | 0.350 |
Why?
| | Electronic Health Records | 2 | 2023 | 286 | 0.350 |
Why?
| | Neoplasms | 2 | 2021 | 2680 | 0.350 |
Why?
| | Chlorides | 2 | 2018 | 104 | 0.340 |
Why?
| | Respiratory Tract Infections | 2 | 2020 | 97 | 0.330 |
Why?
| | Cohort Studies | 9 | 2022 | 2587 | 0.330 |
Why?
| | Databases, Factual | 7 | 2020 | 759 | 0.330 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 38 | 0.330 |
Why?
| | Risk Assessment | 11 | 2020 | 2171 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2021 | 900 | 0.320 |
Why?
| | Pediatrics | 3 | 2016 | 336 | 0.310 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 15 | 0.300 |
Why?
| | Age Factors | 6 | 2021 | 1800 | 0.300 |
Why?
| | Logistic Models | 9 | 2021 | 1117 | 0.300 |
Why?
| | Interleukin-8 | 4 | 2022 | 86 | 0.300 |
Why?
| | Pandemics | 5 | 2023 | 603 | 0.280 |
Why?
| | Matrix Metalloproteinase 8 | 4 | 2017 | 4 | 0.280 |
Why?
| | Renal Replacement Therapy | 2 | 2022 | 25 | 0.270 |
Why?
| | Hypothermia | 2 | 2022 | 24 | 0.270 |
Why?
| | Complement Membrane Attack Complex | 2 | 2020 | 20 | 0.270 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2021 | 62 | 0.260 |
Why?
| | Creatinine | 3 | 2020 | 333 | 0.250 |
Why?
| | Antigens, CD19 | 2 | 2021 | 35 | 0.250 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 1621 | 0.250 |
Why?
| | Guillain-Barre Syndrome | 1 | 2023 | 15 | 0.240 |
Why?
| | Europe | 3 | 2018 | 300 | 0.240 |
Why?
| | Hospitalization | 7 | 2022 | 762 | 0.240 |
Why?
| | Tachycardia, Supraventricular | 1 | 2022 | 16 | 0.240 |
Why?
| | Granzymes | 3 | 2017 | 90 | 0.240 |
Why?
| | Disease Progression | 3 | 2018 | 1432 | 0.240 |
Why?
| | Immunologic Factors | 2 | 2021 | 162 | 0.230 |
Why?
| | Blood Banks | 1 | 2022 | 8 | 0.230 |
Why?
| | Osteonecrosis | 1 | 2022 | 21 | 0.230 |
Why?
| | Muscle Proteins | 2 | 2000 | 135 | 0.230 |
Why?
| | Time Factors | 6 | 2022 | 5156 | 0.230 |
Why?
| | Child, Hospitalized | 1 | 2022 | 28 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2021 | 340 | 0.220 |
Why?
| | C-Reactive Protein | 2 | 2020 | 183 | 0.220 |
Why?
| | Treatment Outcome | 10 | 2021 | 7546 | 0.220 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 61 | 0.220 |
Why?
| | Blood Specimen Collection | 1 | 2021 | 27 | 0.220 |
Why?
| | Delirium | 1 | 2022 | 63 | 0.220 |
Why?
| | Erythrocytes | 1 | 2022 | 249 | 0.210 |
Why?
| | Thrombotic Microangiopathies | 1 | 2020 | 17 | 0.210 |
Why?
| | Vasoconstrictor Agents | 2 | 2020 | 49 | 0.210 |
Why?
| | Inflammation Mediators | 2 | 2020 | 153 | 0.200 |
Why?
| | France | 1 | 2020 | 46 | 0.200 |
Why?
| | Meningitis, Bacterial | 1 | 2020 | 13 | 0.200 |
Why?
| | Intubation | 1 | 2020 | 21 | 0.200 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2000 | 4 | 0.200 |
Why?
| | Chemokine CCL3 | 2 | 2017 | 11 | 0.200 |
Why?
| | Oximetry | 1 | 2020 | 81 | 0.200 |
Why?
| | Fingers | 1 | 2020 | 68 | 0.200 |
Why?
| | Nerve Tissue Proteins | 2 | 2000 | 489 | 0.200 |
Why?
| | Thiamine | 1 | 2019 | 8 | 0.200 |
Why?
| | Hemorrhage | 1 | 2021 | 236 | 0.190 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 239 | 0.190 |
Why?
| | Salvage Therapy | 1 | 2021 | 224 | 0.190 |
Why?
| | Anthracyclines | 1 | 2019 | 34 | 0.190 |
Why?
| | Research Design | 2 | 2020 | 566 | 0.190 |
Why?
| | Emergency Medical Services | 1 | 2021 | 177 | 0.190 |
Why?
| | Clinical Coding | 1 | 2019 | 21 | 0.180 |
Why?
| | Lipids | 1 | 2020 | 276 | 0.180 |
Why?
| | Odds Ratio | 4 | 2022 | 648 | 0.180 |
Why?
| | Homeodomain Proteins | 2 | 2000 | 528 | 0.180 |
Why?
| | Malnutrition | 1 | 2018 | 27 | 0.180 |
Why?
| | Afibrinogenemia | 1 | 2018 | 1 | 0.180 |
Why?
| | Cell Adhesion Molecules | 1 | 2019 | 160 | 0.180 |
Why?
| | Syndrome | 2 | 2017 | 423 | 0.180 |
Why?
| | Macrophage Activation Syndrome | 1 | 2018 | 2 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2013 | 312 | 0.180 |
Why?
| | Ethical Review | 1 | 2018 | 8 | 0.180 |
Why?
| | Nutritional Status | 1 | 2018 | 80 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2018 | 253 | 0.180 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 293 | 0.180 |
Why?
| | Brain Injuries | 1 | 2020 | 141 | 0.170 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 31 | 0.170 |
Why?
| | Chest Wall Oscillation | 1 | 2017 | 5 | 0.170 |
Why?
| | Acute Lung Injury | 1 | 2019 | 61 | 0.170 |
Why?
| | Postoperative Complications | 2 | 2019 | 2093 | 0.170 |
Why?
| | Hemodynamics | 5 | 2021 | 680 | 0.170 |
Why?
| | Body Mass Index | 2 | 2018 | 740 | 0.170 |
Why?
| | Metabolic Diseases | 1 | 2018 | 46 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2019 | 135 | 0.170 |
Why?
| | Phenotype | 6 | 2022 | 2267 | 0.170 |
Why?
| | Case-Control Studies | 5 | 2022 | 1735 | 0.170 |
Why?
| | Comorbidity | 2 | 2018 | 919 | 0.170 |
Why?
| | Health Resources | 1 | 2018 | 73 | 0.170 |
Why?
| | Clinical Alarms | 1 | 2017 | 15 | 0.170 |
Why?
| | User-Computer Interface | 1 | 2019 | 184 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 559 | 0.160 |
Why?
| | Isotonic Solutions | 1 | 2017 | 17 | 0.160 |
Why?
| | Textbooks as Topic | 1 | 2016 | 2 | 0.160 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2017 | 54 | 0.160 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 167 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2018 | 231 | 0.160 |
Why?
| | Ultrasonography | 2 | 2021 | 655 | 0.160 |
Why?
| | Skin | 1 | 2020 | 540 | 0.160 |
Why?
| | Tumor Lysis Syndrome | 1 | 2016 | 8 | 0.160 |
Why?
| | Disabled Children | 1 | 2016 | 43 | 0.150 |
Why?
| | Heart | 1 | 2019 | 501 | 0.150 |
Why?
| | Orthomyxoviridae | 1 | 2016 | 43 | 0.150 |
Why?
| | Patient Discharge | 3 | 2022 | 230 | 0.150 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 67 | 0.150 |
Why?
| | Steroids | 1 | 2016 | 167 | 0.150 |
Why?
| | Virus Diseases | 1 | 2016 | 93 | 0.150 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1032 | 0.150 |
Why?
| | Decision Support Techniques | 1 | 2017 | 154 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2017 | 1168 | 0.140 |
Why?
| | Antibodies, Viral | 3 | 2022 | 291 | 0.140 |
Why?
| | Registries | 1 | 2019 | 654 | 0.140 |
Why?
| | Stroke | 1 | 2023 | 762 | 0.140 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 555 | 0.140 |
Why?
| | ROC Curve | 4 | 2019 | 735 | 0.140 |
Why?
| | Models, Statistical | 2 | 2020 | 571 | 0.140 |
Why?
| | Survival Rate | 4 | 2021 | 1818 | 0.140 |
Why?
| | Cross Infection | 1 | 2015 | 129 | 0.130 |
Why?
| | Models, Biological | 2 | 2019 | 1727 | 0.130 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 30 | 0.130 |
Why?
| | Point-of-Care Systems | 1 | 2015 | 132 | 0.130 |
Why?
| | Recurrence | 1 | 2017 | 1112 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 335 | 0.130 |
Why?
| | Proteolysis | 1 | 2014 | 96 | 0.130 |
Why?
| | Kidney | 1 | 2020 | 1181 | 0.130 |
Why?
| | Program Evaluation | 1 | 2015 | 287 | 0.130 |
Why?
| | Antibodies, Bispecific | 1 | 2013 | 17 | 0.120 |
Why?
| | Macrophage Activation | 1 | 2013 | 42 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 3 | 2022 | 1198 | 0.120 |
Why?
| | Survival Analysis | 4 | 2019 | 1521 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2013 | 24 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2014 | 159 | 0.120 |
Why?
| | Protein Kinases | 1 | 2014 | 207 | 0.120 |
Why?
| | Influenza, Human | 1 | 2016 | 332 | 0.120 |
Why?
| | RNA, Messenger | 2 | 2017 | 1936 | 0.120 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 1943 | 0.120 |
Why?
| | Gagging | 1 | 2011 | 1 | 0.120 |
Why?
| | Metapneumovirus | 1 | 2011 | 4 | 0.110 |
Why?
| | Subcutaneous Emphysema | 1 | 2011 | 6 | 0.110 |
Why?
| | Paramyxoviridae Infections | 1 | 2011 | 6 | 0.110 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 5 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2014 | 224 | 0.110 |
Why?
| | Mediastinal Emphysema | 1 | 2011 | 6 | 0.110 |
Why?
| | Aftercare | 2 | 2022 | 60 | 0.110 |
Why?
| | Clinical Protocols | 3 | 2017 | 155 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2011 | 40 | 0.110 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 164 | 0.110 |
Why?
| | Animals | 11 | 2022 | 25792 | 0.110 |
Why?
| | Adult | 8 | 2022 | 24672 | 0.110 |
Why?
| | Autistic Disorder | 1 | 2011 | 138 | 0.100 |
Why?
| | Immunomodulation | 2 | 2021 | 55 | 0.100 |
Why?
| | Incidence | 3 | 2021 | 1540 | 0.100 |
Why?
| | Equipment Design | 1 | 2011 | 400 | 0.100 |
Why?
| | Bronchoscopy | 1 | 2011 | 143 | 0.100 |
Why?
| | Chromatography, Liquid | 2 | 2021 | 102 | 0.100 |
Why?
| | Mitochondria | 1 | 2014 | 520 | 0.100 |
Why?
| | Acute Disease | 3 | 2018 | 804 | 0.100 |
Why?
| | Vomiting | 1 | 2011 | 182 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3088 | 0.100 |
Why?
| | Rats | 3 | 2022 | 3939 | 0.100 |
Why?
| | Radiography | 1 | 2011 | 806 | 0.100 |
Why?
| | Seizures | 1 | 2011 | 263 | 0.090 |
Why?
| | Neurons | 1 | 2018 | 1483 | 0.090 |
Why?
| | Pilot Projects | 2 | 2022 | 802 | 0.090 |
Why?
| | Morbidity | 2 | 2020 | 139 | 0.090 |
Why?
| | Oxygen | 1 | 2013 | 706 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 907 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 869 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2014 | 686 | 0.090 |
Why?
| | Decision Trees | 2 | 2019 | 63 | 0.080 |
Why?
| | Mice | 7 | 2020 | 10835 | 0.080 |
Why?
| | Fluid Therapy | 2 | 2017 | 45 | 0.080 |
Why?
| | Philadelphia | 2 | 2017 | 12 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2329 | 0.080 |
Why?
| | Factor IX | 1 | 2006 | 4 | 0.080 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 1497 | 0.080 |
Why?
| | Healthcare Disparities | 2 | 2023 | 331 | 0.070 |
Why?
| | Hepatocytes | 1 | 2006 | 118 | 0.070 |
Why?
| | Mice, Inbred BALB C | 2 | 2018 | 1040 | 0.070 |
Why?
| | Cause of Death | 2 | 2017 | 273 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2018 | 2736 | 0.070 |
Why?
| | Adenovirus E1 Proteins | 1 | 2003 | 1 | 0.070 |
Why?
| | HIV Antigens | 1 | 2003 | 3 | 0.070 |
Why?
| | Gene Products, gag | 1 | 2003 | 13 | 0.070 |
Why?
| | AIDS Vaccines | 1 | 2003 | 7 | 0.070 |
Why?
| | Adenoviruses, Human | 1 | 2003 | 40 | 0.070 |
Why?
| | Immunization, Secondary | 1 | 2003 | 27 | 0.070 |
Why?
| | PAX7 Transcription Factor | 2 | 2000 | 4 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 1622 | 0.060 |
Why?
| | Academic Medical Centers | 2 | 2017 | 356 | 0.060 |
Why?
| | DNA-Binding Proteins | 2 | 2000 | 1187 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 3067 | 0.060 |
Why?
| | Thrombomodulin | 1 | 2022 | 7 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2016 | 968 | 0.060 |
Why?
| | Neutralization Tests | 1 | 2022 | 74 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2022 | 73 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2020 | 2579 | 0.060 |
Why?
| | Immunoassay | 1 | 2022 | 89 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2022 | 145 | 0.060 |
Why?
| | Glasgow Coma Scale | 1 | 2022 | 50 | 0.060 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2022 | 42 | 0.060 |
Why?
| | Blood Component Transfusion | 1 | 2021 | 12 | 0.060 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 96 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2022 | 57 | 0.060 |
Why?
| | Transcription Factors | 2 | 2000 | 1482 | 0.060 |
Why?
| | Italy | 1 | 2021 | 102 | 0.060 |
Why?
| | Antifibrinolytic Agents | 1 | 2021 | 25 | 0.060 |
Why?
| | Models, Theoretical | 2 | 2015 | 478 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 112 | 0.050 |
Why?
| | Canada | 1 | 2021 | 195 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 105 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2022 | 180 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 95 | 0.050 |
Why?
| | Age Distribution | 1 | 2021 | 200 | 0.050 |
Why?
| | Neuroimaging | 1 | 2021 | 98 | 0.050 |
Why?
| | Propensity Score | 1 | 2021 | 136 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 68 | 0.050 |
Why?
| | Piperacillin | 1 | 2020 | 7 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 746 | 0.050 |
Why?
| | Penicillanic Acid | 1 | 2020 | 11 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 538 | 0.050 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 26 | 0.050 |
Why?
| | Temperature | 1 | 2022 | 395 | 0.050 |
Why?
| | Erythrocyte Count | 1 | 2020 | 23 | 0.050 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 39 | 0.050 |
Why?
| | APACHE | 1 | 2020 | 20 | 0.050 |
Why?
| | Streptococcus agalactiae | 1 | 2020 | 11 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 32 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2020 | 155 | 0.050 |
Why?
| | Age of Onset | 1 | 2021 | 310 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2020 | 82 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2021 | 3576 | 0.050 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2000 | 51 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2003 | 522 | 0.050 |
Why?
| | Punctures | 1 | 2019 | 28 | 0.050 |
Why?
| | Ligation | 1 | 2019 | 52 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 103 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2020 | 216 | 0.050 |
Why?
| | Streptococcal Infections | 1 | 2020 | 56 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2000 | 99 | 0.050 |
Why?
| | False Positive Reactions | 1 | 2020 | 217 | 0.050 |
Why?
| | Inpatients | 1 | 2023 | 269 | 0.050 |
Why?
| | Cecum | 1 | 2019 | 66 | 0.050 |
Why?
| | Fungi | 1 | 2020 | 62 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 421 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2020 | 58 | 0.050 |
Why?
| | Rhabdomyosarcoma | 1 | 1999 | 44 | 0.050 |
Why?
| | Nephritis, Interstitial | 1 | 2020 | 47 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 1999 | 42 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2020 | 353 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2020 | 159 | 0.050 |
Why?
| | Viruses | 1 | 2020 | 75 | 0.050 |
Why?
| | RNA, Viral | 1 | 2020 | 326 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 375 | 0.050 |
Why?
| | Regression Analysis | 1 | 2021 | 591 | 0.050 |
Why?
| | Cystatin C | 1 | 2019 | 31 | 0.050 |
Why?
| | Osteopontin | 1 | 2019 | 48 | 0.050 |
Why?
| | Lactic Acid | 1 | 2019 | 85 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2022 | 423 | 0.050 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 101 | 0.050 |
Why?
| | South America | 1 | 2018 | 30 | 0.050 |
Why?
| | Translocation, Genetic | 1 | 2000 | 261 | 0.050 |
Why?
| | Area Under Curve | 1 | 2019 | 334 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2000 | 165 | 0.050 |
Why?
| | Linear Models | 1 | 2020 | 402 | 0.050 |
Why?
| | Asia | 1 | 2018 | 93 | 0.050 |
Why?
| | Neurosurgery | 1 | 2020 | 78 | 0.040 |
Why?
| | Recovery of Function | 1 | 2020 | 249 | 0.040 |
Why?
| | Stroke Volume | 1 | 2021 | 407 | 0.040 |
Why?
| | Ghrelin | 1 | 2018 | 23 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2020 | 445 | 0.040 |
Why?
| | Coma | 1 | 2018 | 41 | 0.040 |
Why?
| | Hyperphagia | 1 | 2018 | 34 | 0.040 |
Why?
| | Hospital Costs | 1 | 2019 | 99 | 0.040 |
Why?
| | North America | 1 | 2018 | 171 | 0.040 |
Why?
| | Infant, Premature | 1 | 2020 | 269 | 0.040 |
Why?
| | Neutrophils | 1 | 2019 | 294 | 0.040 |
Why?
| | Leptin | 1 | 2018 | 100 | 0.040 |
Why?
| | Ohio | 1 | 2017 | 34 | 0.040 |
Why?
| | Calcitonin | 1 | 2017 | 38 | 0.040 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 24 | 0.040 |
Why?
| | International Cooperation | 1 | 2017 | 124 | 0.040 |
Why?
| | Acidosis | 1 | 2017 | 56 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2018 | 124 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2017 | 53 | 0.040 |
Why?
| | Vital Signs | 1 | 2017 | 41 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2017 | 85 | 0.040 |
Why?
| | Chemokines, CC | 1 | 2016 | 33 | 0.040 |
Why?
| | Kinetics | 1 | 2019 | 1523 | 0.040 |
Why?
| | Bacteria | 1 | 2020 | 412 | 0.040 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2016 | 34 | 0.040 |
Why?
| | Spleen | 1 | 2017 | 438 | 0.040 |
Why?
| | Nasopharynx | 1 | 2016 | 46 | 0.040 |
Why?
| | Neuroblastoma | 1 | 1999 | 351 | 0.040 |
Why?
| | Myeloblastin | 1 | 2015 | 5 | 0.040 |
Why?
| | Specimen Handling | 1 | 2016 | 92 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 267 | 0.040 |
Why?
| | Melanoma | 1 | 1999 | 430 | 0.040 |
Why?
| | Anesthesia | 1 | 2017 | 154 | 0.040 |
Why?
| | Obesity | 1 | 2022 | 919 | 0.040 |
Why?
| | Pleural Effusion | 1 | 2015 | 44 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2015 | 126 | 0.040 |
Why?
| | Glucose | 1 | 2018 | 613 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 266 | 0.030 |
Why?
| | Pregnancy | 1 | 2022 | 2704 | 0.030 |
Why?
| | Fever | 1 | 2015 | 121 | 0.030 |
Why?
| | Pneumothorax | 1 | 2015 | 49 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 2015 | 146 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 2183 | 0.030 |
Why?
| | Motor Activity | 1 | 2017 | 321 | 0.030 |
Why?
| | Inflammation | 1 | 2020 | 836 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2017 | 219 | 0.030 |
Why?
| | Chaperonin 60 | 1 | 2014 | 7 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 978 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1223 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2017 | 354 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2016 | 154 | 0.030 |
Why?
| | Sleep | 1 | 2018 | 423 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 300 | 0.030 |
Why?
| | Caspase 3 | 1 | 2014 | 160 | 0.030 |
Why?
| | Respiratory Rate | 1 | 2013 | 19 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 434 | 0.030 |
Why?
| | Heat-Shock Response | 1 | 2014 | 44 | 0.030 |
Why?
| | Observer Variation | 1 | 2015 | 590 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 521 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2013 | 17 | 0.030 |
Why?
| | Quality Improvement | 1 | 2017 | 366 | 0.030 |
Why?
| | Sex Factors | 1 | 2017 | 1020 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 232 | 0.030 |
Why?
| | Genetic Vectors | 2 | 2006 | 429 | 0.030 |
Why?
| | Down Syndrome | 1 | 2013 | 51 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2013 | 236 | 0.030 |
Why?
| | Mortality | 1 | 2014 | 147 | 0.030 |
Why?
| | Sirolimus | 1 | 2014 | 166 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 932 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2014 | 692 | 0.030 |
Why?
| | Brain | 1 | 2022 | 2023 | 0.030 |
Why?
| | Burns | 1 | 2013 | 108 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 847 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2014 | 606 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2275 | 0.030 |
Why?
| | Cell Survival | 1 | 2014 | 957 | 0.030 |
Why?
| | Biomedical Research | 1 | 2015 | 349 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 322 | 0.030 |
Why?
| | Apoptosis | 1 | 2014 | 1653 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 310 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2006 | 214 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2006 | 169 | 0.020 |
Why?
| | Gene Transfer Techniques | 1 | 2006 | 148 | 0.020 |
Why?
| | Adenoviridae | 1 | 2006 | 345 | 0.020 |
Why?
| | Immunization Schedule | 1 | 2003 | 22 | 0.020 |
Why?
| | Vaccinia virus | 1 | 2003 | 19 | 0.020 |
Why?
| | Vaccines, DNA | 1 | 2003 | 16 | 0.020 |
Why?
| | Injections, Intramuscular | 1 | 2003 | 62 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2006 | 330 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2003 | 89 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2006 | 287 | 0.020 |
Why?
| | HeLa Cells | 1 | 2003 | 497 | 0.010 |
Why?
| | Pan troglodytes | 1 | 2003 | 190 | 0.010 |
Why?
| | Paired Box Transcription Factors | 1 | 1999 | 51 | 0.010 |
Why?
| | Plasmids | 1 | 1999 | 282 | 0.010 |
Why?
| | Aged | 1 | 2016 | 17520 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1999 | 418 | 0.010 |
Why?
| | Cell Line | 1 | 2003 | 2474 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1999 | 194 | 0.010 |
Why?
| | Exons | 1 | 1999 | 440 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1999 | 1039 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 24058 | 0.010 |
Why?
| | Base Sequence | 1 | 1999 | 2326 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1999 | 2077 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1999 | 1119 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1999 | 3051 | 0.010 |
Why?
| | Models, Genetic | 1 | 1999 | 893 | 0.010 |
Why?
|
|
Fitzgerald's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|